Compare Illumina, Inc. (ILMN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Novartis AG — how do they compare? Illumina, Inc. trades at $184.68 (market cap $27.94B), while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG is far larger — about 10.4× Illumina, Inc.'s market cap, and Novartis AG pays a 3.17% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | NVS | |
|---|---|---|
Market Cap | $27.94B | $290.25B |
Sector | Health | Health |
52-Week High | $194.33 | $168.62 |
52-Week Low | $91.00 | $113.50 |
Enterprise Value | $29.33B | $330.27B |
Dividend Yield | — | 3.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
